Healthcare deal structures: licensing and milestones

Why healthcare uses more deal structures than most sectors

A generalist M&A interview mostly assumes one structure: a buyer pays a price, in cash, stock, or some mix, for the whole target company, and the deal closes. Healthcare uses that structure constantly too, but it also uses several others that exist for one shared reason: a large share of value in this sector is genuinely uncertain at the moment a deal is negotiated, tied to a clinical trial outcome, a regulatory decision, or a commercial launch that hasn't happened yet. A structure that forces both sides to agree on a single, fixed price today, with no adjustment for how that uncertainty resolves, tends to produce a standoff: the seller wants credit for the upside case, the buyer doesn't want to pay for value that might never materialize. Healthcare's distinctive deal structures are, in effect, ways of not having that argument, by making the price itself contingent on the outcome.

Licensing and partnership deals

A licensing deal is the sector's most common alternative to an outright acquisition, especially in biopharma. Instead of buying a company, a larger pharma company acquires the rights to develop and commercialize a specific drug candidate, or a specific set of candidates, from a smaller biotech that discovered it. The smaller company keeps its independence and often keeps rights to other assets in its pipeline, while gaining the capital and, often, the larger commercial infrastructure needed to get the specific licensed asset through the rest of development and to market.

The payment structure typically has three components. An upfront payment is paid at signing, giving the smaller company immediate capital regardless of how the asset eventually performs. Milestone payments are paid later, each one triggered by a specific event: completing a clinical trial, receiving regulatory approval, or hitting a specified level of commercial sales once the product launches. A royalty is paid on actual sales once the product is commercial, giving the smaller company an ongoing share of the asset's success for as long as it stays on the market.

This structure lets both sides get something they couldn't get from a single fixed price. The smaller company gets capital today without giving up the entire asset's future upside, and gets to keep developing its other pipeline assets independently. The larger company gets access to a promising asset without paying in full for value that hasn't yet been proven, spreading its payments out to match when the underlying risk actually resolves. It's also a direct alternative to the other main way a small biotech funds itself, raising equity from public markets, covered in biotech IPOs and follow-on offerings: a licensing deal brings in a partner's capital and expertise without diluting existing shareholders the way an equity raise does, though it comes at the cost of sharing the asset's eventual upside with that partner instead.

Why milestones are staged the way they are

The specific sequence of milestone payments isn't arbitrary. Each milestone is generally tied to a point where a meaningful amount of uncertainty resolves, which is the same logic underlying the risk-adjusted valuation approach covered in how biotech companies are valued: as a drug candidate clears each successive clinical and regulatory hurdle, the remaining uncertainty about its eventual success shrinks, and the size of the milestone payment tied to that hurdle reflects how much value that specific step unlocks. A milestone tied to completing a late-stage clinical trial is typically sized larger than one tied to an earlier, less determinative step, because clearing the later trial resolves a much bigger share of the asset's total remaining uncertainty.

This staging also protects the buyer from the single biggest risk in any healthcare deal: paying fully upfront for an asset that later fails. By spreading payment across development and commercial milestones, the buyer only pays the largest portions of the total deal value once the asset has actually demonstrated that it's likely to succeed, which is a very different risk profile than a conventional acquisition where the full purchase price changes hands at closing regardless of what happens to the business afterward. A regulatory approval milestone specifically hands the buyer some protection against the approval risk covered in regulatory risk in healthcare M&A, since that portion of the payment simply never gets made if the asset doesn't clear the regulator.

This same logic is exactly why large pharma companies use licensing so heavily to manage the patent cliff dynamics covered in pharma business models, pipelines, and patent cliffs: licensing lets a company add a promising external asset to its pipeline without committing the full economic value of an outright acquisition to something that hasn't yet cleared its remaining development risk.

Contingent value rights in outright M&A

A contingent value right, or CVR, applies the same logic inside a full acquisition rather than a licensing deal. When a buyer acquires an entire company, including assets whose value depends on a future clinical or regulatory outcome, it can pay a base price at closing and issue CVRs to the seller's shareholders that pay out additional consideration only if a specified event occurs, most commonly a clinical trial succeeding or a regulatory approval being granted by a certain date.

This is the same economic idea as an earn-out used in general M&A, adapted to healthcare's specific binary-outcome risk: instead of the contingency being tied to a financial metric like revenue or EBITDA, it's tied to a scientific or regulatory event. CVRs let a buyer avoid overpaying for a target's most uncertain assets while still giving the seller's shareholders a path to full value if those assets succeed, and they're a common feature of biopharma acquisitions where a meaningful part of the target's value sits in early or mid-stage pipeline assets rather than an already-approved, already-selling product.

Royalty monetization

A different structure altogether applies once a drug is already approved and generating sales: royalty monetization, where a company that holds the right to receive a royalty on an approved drug's sales, whether the original inventor, an academic institution, or a company that licensed the asset out to a bigger partner, sells that future royalty stream to an investor in exchange for a lump sum of cash today. This converts a stream of future, ongoing payments into immediate capital, which can be valuable for a smaller company that would rather fund its current operations or pipeline than wait years to collect royalties as they come in.

From the buyer's side, a royalty stream on an approved, already-selling drug is an attractive asset precisely because most of the risk that makes biopharma valuation so complicated, the risk that the drug never reaches the market at all, has already resolved. The investor is underwriting commercial risk, how the drug's sales trajectory will actually evolve, rather than the far larger binary risk of approval, which is why royalty monetization functions almost like a separate, more bond-like asset class within the broader biopharma world.

Carve-outs and the asset-versus-stock decision

Large pharma and medtech companies periodically divest business lines that no longer fit their strategic focus, a transaction structure called a carve-out. A conglomerate-style pharma company might divest a mature, slower-growing product line to focus capital and management attention on its higher-growth pipeline, selling the divested business to either a strategic buyer who values it more highly because it fits their own core focus, or to a financial sponsor who sees an opportunity to run it as a standalone, more focused business.

These transactions also raise a structural question that shows up in general M&A but carries specific tax and liability consequences in pharma: whether the deal is structured as a sale of the legal entity's stock or as a sale of the specific assets and product rights being divested. An asset sale can let a buyer get a stepped-up tax basis in the acquired assets, while a stock sale generally carries over the target entity's existing tax attributes, a distinction covered in more general terms in the M&A terms guide. In a carve-out specifically, the choice also affects which liabilities, ongoing product liability claims, existing supply contracts, and similar obligations, actually transfer with the divested business, which is often a heavily negotiated point given how important large legal and regulatory obligations can be in this sector.

How these structures actually come up in interviews

Rarely as a request to define a term in isolation. The more common framing is a "walk me through why a pharma company would license out a drug instead of just developing it themselves" question, or a "how would you structure a deal for a biotech with one promising but unproven asset" question, both of which are really asking whether you understand that healthcare deal structures exist to manage uncertainty over time, not just to move money from one party to another. A candidate who can explain the upfront-milestone-royalty logic, and why it mirrors the risk-adjusted valuation approach used to value the underlying asset in the first place, is demonstrating exactly the kind of connected understanding these questions are designed to surface.

Practice question

Why would a biotech license a drug to a larger pharma company instead of just developing and selling it themselves?

Mostly for capital and commercial reach, without giving up the entire asset. Developing a drug through the rest of clinical trials, regulatory approval, and a commercial launch is expensive and requires infrastructure, sales forces, manufacturing at scale, regulatory expertise, that a smaller biotech often doesn't have and would take years to build on its own. Licensing the asset to a larger partner gets the biotech an upfront cash payment immediately, plus a series of milestone payments as the drug clears further clinical and regulatory hurdles, plus an ongoing royalty once it's approved and selling, all without the biotech needing to fund the rest of development itself or build commercial infrastructure from scratch. It also lets the biotech keep its remaining pipeline assets fully independent, rather than needing to sell the whole company to access capital for just one program. The tradeoff is that the biotech gives up full ownership of the licensed asset's eventual value in exchange for reduced risk and faster access to capital today, which is a reasonable trade for a company that doesn't have the resources to go it alone on a single asset's full development and commercialization.

What the interviewer is listening for: whether you can name all three payment components, upfront, milestones, and royalty, and explain why staging payments this way manages risk for both sides rather than just reciting the structure. Bonus points for connecting it back to why standard biotech valuation is also risk-adjusted rather than a simple DCF.